| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0ea9fa599ee0f0a5b8f2f20f082c071 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-64 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2017-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba6b3c6c5f5c1f951879d3d9f3c946ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36f8168bf6536fe5df998c12cb4cb99b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0ec68cd27c198b27a2e6b2b6edce243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20b7579ea6b1f3cdbafeaa4e8430b62e |
| publicationDate |
2018-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3416667-A1 |
| titleOfInvention |
Peptide agonists and antagonists of tlr4 activation |
| abstract |
A group of peptides is provided which activate or inhibit toll-like receptor 4 (TLR4) and may be used to modulate inflammatory signaling and host defense pathways. The peptides were derived in silico and tested in vitro in cell cultures. These peptides may be used in the preparation of immunomodulatory compositions such as vaccine adjuvants and in pharmaceutical compositions for immunomodulation of the innate immune system such as vaccine adjuvants. The peptides may also be used in the preparation of TLR4 activators, TLR4 inhibitors and MD2 labels, e.g., for research purposes. |
| priorityDate |
2016-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |